Marinus Pharmaceuticals Inc. [NASDAQ: MRNS] stock went on a downward path that fall over -0.62% on Wednesday, amounting to a one-week price increase of more than 69.15%. The company report on September 14, 2020 that Ganaxolone Achieves Primary Endpoint in Phase 3 Trial for CDKL5 Deficiency Disorder (CDD), a Rare Form of Genetic Epilepsy.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced positive top-line results from its registrational Phase 3 clinical trial (Marigold Study) evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy with refractory seizures.
In the trial, patients given ganaxolone showed a significant 32.2 percent median reduction in 28-day major motor seizure frequency, compared to a 4.0 percent reduction for those receiving the placebo, achieving the primary endpoint (p=0.002). The trial’s primary efficacy endpoint was the percentage change in 28-day frequency of major motor seizures during the double-blind phase relative to the 6-week prospective baseline period. Ganaxolone was generally well tolerated with a safety profile consistent with previous clinical studies. The most frequent adverse event was somnolence.
Over the last 12 months, MRNS stock rose by 82.76%. The average equity rating for MRNS stock is currently 1.40, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $378.90 million, with 99.77 million shares outstanding and 82.92 million shares in the current float. Compared to the average trading volume of 4.58M shares, MRNS stock reached a trading volume of 11032612 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Marinus Pharmaceuticals Inc. [MRNS]:
H.C. Wainwright have made an estimate for Marinus Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 01, 2020. The new note on the price target was released on July 01, 2020, representing the official price target for Marinus Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $4.50, while Craig Hallum analysts kept a Buy rating on MRNS stock.
The Average True Range (ATR) for Marinus Pharmaceuticals Inc. is set at 0.29 The Price to Book ratio for the last quarter was 3.42, with the Price to Cash per share for the same quarter was set at 0.89.
MRNS Stock Performance Analysis:
Marinus Pharmaceuticals Inc. [MRNS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 69.15. With this latest performance, MRNS shares gained by 65.63% in over the last four-week period, additionally plugging by 146.51% over the last 6 months – not to mention a rise of 82.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNS stock in for the last two-week period is set at 80.76, with the RSI for the last a single of trading hit 87.37, and the three-weeks RSI is set at 73.29 for Marinus Pharmaceuticals Inc. [MRNS]. The present Moving Average for the last 50 days of trading for this stock 1.95, while it was recorded at 2.49 for the last single week of trading, and 2.11 for the last 200 days.
Insight into Marinus Pharmaceuticals Inc. Fundamentals:
Return on Total Capital for MRNS is now -66.58, given the latest momentum, and Return on Invested Capital for the company is -68.02. Return on Equity for this stock declined to -69.34, with Return on Assets sitting at -62.18. When it comes to the capital structure of this company, Marinus Pharmaceuticals Inc. [MRNS] has a Total Debt to Total Equity ratio set at 3.97. Additionally, MRNS Total Debt to Total Capital is recorded at 3.82, with Total Debt to Total Assets ending up at 3.53. Long-Term Debt to Equity for the company is recorded at 5.11, with the Long-Term Debt to Total Capital now at 3.33.
Reflecting on the efficiency of the workforce at the company, Marinus Pharmaceuticals Inc. [MRNS] managed to generate an average of -$1,353,025 per employee.Marinus Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.50 and a Current Ratio set at 11.50.
MRNS Stock EPS
With the latest financial reports released by the company, Marinus Pharmaceuticals Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -8.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Marinus Pharmaceuticals Inc. go to 20.00%.
Marinus Pharmaceuticals Inc. [MRNS] Insider Position Details
There are presently around $311 million, or 77.80% of MRNS stock, in the hands of institutional investors. The top three institutional holders of MRNS stocks are: AVORO CAPITAL ADVISORS LLC with ownership of 11,960,000, which is approximately 92.903% of the company’s market cap and around 0.63% of the total institutional ownership; LION POINT CAPITAL, LP, holding 10,873,340 shares of the stock with an approximate value of $34.58 million in MRNS stocks shares; and BOXER CAPITAL, LLC, currently with $30.53 million in MRNS stock with ownership of nearly New of the company’s market capitalization.
Positions in Marinus Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 67 institutional holders increased their position in Marinus Pharmaceuticals Inc. [NASDAQ:MRNS] by around 32,812,595 shares. Additionally, 26 investors decreased positions by around 3,680,332 shares, while 12 investors held positions by with 61,166,494 shares. The mentioned changes placed institutional holdings at 97,659,421 shares, according to the latest SEC report filing. MRNS stock had 28 new institutional investments in for a total of 7,511,330 shares, while 7 institutional investors sold positions of 1,386,419 shares during the same period.